Further, treatment with the hsp90 inhibitor AUY922 was also demonstrated to disrupt the chaperone association of hsp90 with ATR and CHK1, thereby depleting their expression levels in breast cancer cells [6]. The gene discussed is HSP90AA1; the disease is breast carcinoma.